<DOC>
	<DOCNO>NCT00003332</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug radiation therapy and/or surgery may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy , consist gemcitabine cisplatin , follow chemotherapy radiation therapy and/or surgery treat patient pancreatic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Chemotherapy Radiation Therapy and/or Surgery Treating Patients Who Have Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient locally advanced pancreatic cancer induction therapy gemcitabine cisplatin . - Determine maximum tolerate dose gemcitabine cisplatin chemotherapy combine radiation therapy patient . - Determine overall response rate patient combined modality regimen follow induction chemotherapy . - Determine resectability rate locally advance pancreatic lesion treat regimen . - Determine time failure entire treatment program . OUTLINE : This dose-escalation study . Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 . Following gemcitabine , patient receive cisplatin IV 1 hour day 1 , 8 , 15 . Course repeat every 4 week . After 2 course induction chemotherapy , disease restaged . Patients may receive radiotherapy addition chemotherapy . Radiotherapy give daily 5 week 3 day . During radiotherapy , cohorts 3 patient treat escalate dos gemcitabine cisplatin administer described induction chemotherapy . The maximum tolerated dose ( MTD ) define low dose 2 6 2 3 patient experience dose limit toxicity . When MTD determine , additional patient accrue study receive dose level immediately MTD . If 2 course induction chemotherapy gemcitabine cisplatin tumor radiographically consider resectable operating surgeon , patient undergoes surgical exploration laparoscopy stag verification resectability . If tumor find resectable without evidence distant disease , patient undergoes complete surgical resection radiation plus adjuvant gemcitabine cisplatin . Patients follow every 3 month death . PROJECTED ACCRUAL : Approximately 15-36 patient accrued Phase I portion study 14-25 patient accrue Phase II portion study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm localized adenocarcinoma pancreas consider unresectable Measurable evaluable disease No metastatic disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : Granulocyte count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin le 3.0 mg/dL Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Other : No serious concurrent systemic disorder No active infection uncontrolled infection Not pregnant Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify Other : At least 1 month since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>